Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Accounts Payables (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Accounts Payables for 13 consecutive years, with $48.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 12.11% to $48.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.9 million, a 12.11% increase, with the full-year FY2025 number at $48.9 million, up 12.11% from a year prior.
  • Accounts Payables was $48.9 million for Q4 2025 at Madrigal Pharmaceuticals, up from $44.9 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $48.9 million in Q4 2025 to a low of $1.1 million in Q2 2021.
  • A 5-year average of $24.1 million and a median of $21.5 million in 2021 define the central range for Accounts Payables.
  • Biggest YoY gain for Accounts Payables was 2002.26% in 2021; the steepest drop was 78.68% in 2021.
  • Madrigal Pharmaceuticals' Accounts Payables stood at $21.4 million in 2021, then rose by 11.46% to $23.8 million in 2022, then rose by 17.67% to $28.0 million in 2023, then surged by 55.48% to $43.6 million in 2024, then rose by 12.11% to $48.9 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Accounts Payables are $48.9 million (Q4 2025), $44.9 million (Q3 2025), and $38.0 million (Q2 2025).